CDT Equity (CDT) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oragenics is the larger company by market cap ($2.1 million vs $29,108), about 70.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDT | OGEN |
|---|---|---|
| Share price | $0.718 | $0.456 |
| Market cap | $29.11K | $2.06M |
| 1-day change | -10.25% | -1.51% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $80,767.07 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28,400.00 | $1.45 |
| 52-week low | $0.70 | $0.45 |
| Distance from 52-week high | -100.00% | -68.55% |
| Average volume | 188.27K | 29.72K |
| Shares outstanding | 40.54K | 4.51M |
| Employees | 4 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oragenics is about 70.7 times larger than CDT Equity by market value ($2.06M vs $29.11K).
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
CDT vs OGEN FAQ
Which is bigger, CDT Equity or Oragenics?
Oragenics (OGEN) is larger, with a market capitalization of $2.06M compared with $29.11K for CDT Equity (CDT).
Are CDT Equity and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.